Freenome is a biotechnology company driven to provide the tools needed to detect, treat and prevent cancer using routing blood draw. This company was founded in 2014 by Gabe Otte, Riley Ennis, Charles Roberts and is headquartered in South San Francisco, CA. Freenome combines molecular biology with advanced computational biology and machine learning to help with early cancer detection.
As Freenome is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Freenome, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
How to buy Freenome stock?
To invest in a private company like Freenome through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)
Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
Can you sell Freenome stock?
Yes, you may sell the Freenome stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
How to sell Freenome stock?
If you hold private company shares of Freenome – whether as an employee or an early investor – Forge can help you sell them.
Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your Freenome on our platform.
Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
To learn more about Freenome stock
Is Freenome a public company?
No, Freenome is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
What is Freenome’s stock price?
Freenome is a privately held company and therefore does not have a public stock price. However, you may access Freenome private market stock price with Forge Data.
What is Freenome’s stock ticker symbol?
Freenome does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.
Freenome investors also invested in these private companies
In early 2022, Freenome surpassed $1 billion in lifetime financing after raking in two nine-figure funding rounds barely a month apart, with plans to use the money to launch new studies of its cancer blood tests. Two years later, the company is adding to its coffers once again, with an eye toward both keeping those studies afloat and continuing to develop additional disease-detecting liquid biopsy tests. The latest funding round weighed in at $254 million, Freenome announced Thursday. It was led by Roche, which has participated in all of Freenome’s previous fundraising sessions and was also responsible for the $290 million contribution at the start of 2022 that brought Freenome’s total past the $1 billion mark.
Walgreens and biotech firm Freenome have announced a multi-year partnership to advance clinical studies of Freenome's blood-based tests for early cancer detection. Walgreens will use its national footprint and patient insights to engage diverse patient populations in Freenome's multi-cancer research program. The partnership will also work on building risk-prediction models and population health software to help identify people eligible for standard-of-care cancer detection testing.
Forge is your trusted partner to buy and sell Freenome stock
Forge is the trusted platform for buying and selling private company stock. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.
Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.
The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.
Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.
May Private Market Update
